ArticlePloS one2025
Antioxidant and antidiabetic effects of Angylocalyx oligophyllus leaves aqueous extract in pregnant diabetic rats: Feto-maternal repercussions.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregestational diabetes mellitus can lead to many adverse outcomes during pregnancy both in the mother and her embryo/fetus. Plant-based products are empirically used as an alternative strategy to reduce these disorders. To investigate the effects of the Angylocalyx oligophyllus leaves aqueous extract on diabetes-induced metabolic, reproductive and fetal developmental disorders in pregnant diabetic rats, the in vitro anti-α-amylase and antioxidant plant effects first were evaluated. Then, adult virgin female rats primarily made diabetic by streptozotocin (35 mg/kg) and normal ones were mated with adult male rats. The pregnant rats were distributed into normal and diabetic control groups receiving distilled water, and diabetic rats groups treated with the plant extract doses (50, 100 and 200 mg/kg) or Glibenclamide (standard; 10 mg/kg). Animals were orally treated from 1st to 19th day of gestation, daily weighted, blood glucose levels measured on 1st, 5th, 10th, 15th and 20th gestation days (gd). At the end of pregnancy, maternal diabetic and reproductive parameters, and fetal morphological parameters were analyzed. At the gd 20, there were significant hyperglycemia, altered glucose tolerance, increased total cholesterol, triglycerides, transaminases, liver MDA, SOD, CAT and GSH, reabsorptions sites, post-implantation losses and death fetuses, reduced 17-β-estradiol and numbers of pancreatic cells, corpora luteum, implantation sites and live fetuses in non-treated diabetic mothers, associated with reduced weight and placental and caudal malformations in offsprings. The A. oligophyllus leaves aqueous extract induced significant anti-α-amylase and antioxidant activities in vitro. In pregnant diabetic rats, the plant significantly (p < 0.5-p < 0.001) reduced the serum levels of glucose, total cholesterol, triglycerides, LDL-cholesterol, transaminases liver MDA, SOD, CAT and GSH, and post-implantation losses, increased the serum HDL-cholesterol and 17-β-estradiol, the number of pancreatic cells, implantation sites and live fetuses, while reducing placental and caudal malformations, and normalizing fetal weights in offsprings. The A. oligophyllus supplementation during pregnancy would be beneficial in preventing reproductive complications related to diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.